Saves everyone looking it up:
Further details on the Phase IIb trial design including the expected timing for trial application and approval for the Phase IIb trial of ATL1102 in non-ambulant DMD patients to be conducted in Europewill be communicated to the market once the final opinion is received from PDCO following their 15 October 2021 meeting.
Ann: Positive feedback received on Paediatric Investigation Plan, page-98
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M | |||
| Open | High | Low | Value | Volume |
| 7.9¢ | 7.9¢ | 7.6¢ | $26.62K | 343.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 113467 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.7¢ | 98248 | 1 |
View Market Depth
| Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.7¢ |
Change
0.000 ( 1.28 %) |
||||
| Open | High | Low | Volume | ||
| 7.9¢ | 7.9¢ | 7.7¢ | 14800 | ||
| Last updated 15.52pm 06/05/2024 ? | |||||
| PER (ASX) Chart |